Ten-year changes in clinical characteristics and antiviral treatment patterns of chronic hepatitis B in China: a CR-HepB-based real-world study.
10.3760/cma.j.cn501113-20230518-00226
- VernacularTitle:中国慢性乙型肝炎临床特征和抗病毒治疗模式十年变迁：基于CR-HepB的真实世界研究
- Author:
Xiao Qian XU
1
;
Hao WANG
2
;
Shan SHAN
3
;
Hong YOU
3
;
Yue Min NAN
4
;
Xiao Yuan XU
5
;
Zhong Ping DUAN
6
;
Lai WEI
7
;
Jin Lin HOU
8
;
Hui ZHUANG
9
;
Ji Dong JIA
3
;
Yuan Yuan KONG
1
Author Information
1. Clinical Epidemiology and EBM Unit, Beijing Friendship Hospital, Capital Medical University, Beijing Clinical Research Institute, Beijing 100050, China.
2. Beijing Clinical Research Institute, Beijing 100050, China.
3. Liver Research Center, Beijing Friendship Hospital, Capital Medical University, National Clinical Research Center for Digestive Diseases, Beijing 100050, China.
4. Department of Traditional and Western Medical Hepatology, The Third Hospital of Hebei Medical University, Shijiazhuang 050051, China.
5. Department of Infectious Diseases, Peking University First Hospital, Beijing 100034, China.
6. Artificial Liver Center, Beijing You'an Hospital, Capital Medical University, Beijing 100069, China.
7. Department of Hepatology, Beijing Tsinghua Changgung Hospital, Beijing 100044, China.
8. Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
9. Department of Microbiology and Parasitology, Peking University Health Science Center, Beijing 100191, China.
- Collective Name:China Registry of Hepatitis B (CR-HepB) Group
- Publication Type:Journal Article
- Keywords:
CR-HepB;
China Registry of Hepatitis B;
Chronic hepatitis B;
Liver cirrhosis;
Treatment patterns
- MeSH:
Humans;
Male;
Female;
Adult;
Aged, 80 and over;
Antiviral Agents/therapeutic use*;
Hepatitis B, Chronic/epidemiology*;
Hepatitis B e Antigens;
Hepatitis B/drug therapy*;
Hepatitis B Surface Antigens;
Hepatitis A;
Liver Cirrhosis/drug therapy*;
China/epidemiology*;
Registries;
Hepatitis B virus/genetics*;
DNA, Viral
- From:
Chinese Journal of Hepatology
2023;31(7):698-704
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To understand ten-year changes in clinical characteristics and antiviral treatment patterns of chronic hepatitis B in China. Methods: Patients with chronic HBV infection:demographic, virologic, hematologic, blood biochemistry, and antiviral treatment data were extracted from the China Registry of Hepatitis B (CR-HepB) database between 2012 and 2022 for descriptive statistics and change trend analysis. Multiple group comparisons were conducted using the Kruskal Wallis H test, while counting data was compared between groups using χ (2) test. Results: A total of 180 012 patients with chronic HBV infection were included, with a median age of 40 years old, and a male proportion accounting for 60.2%. The HBeAg positive rate was 43.3%. Over time, the median age of new patients each year increased from 39 to 47 years, while the HBeAg positive rate decreased from 51.3% to 32.8%. The initial diagnosis of patients was mainly CHB (71.4%), followed by hepatitis B cirrhosis (11.8%), inactive HBsAg carrier status (10.6%), and chronic HBV carrier status (6.2%). Among the newly registered patients every year from 2012 to 2022, the proportion of hepatitis B cirrhosis remained stable, but after 2019, the proportion of CHB increased and the proportion of other diagnoses decreased. The proportion of patients with cirrhosis increased with age in different age groups, with 3.5%, 19.3%, and 30.4% in the < 40, 40-69, and≥70 age groups, respectively. The proportion of women in patients with cirrhosis also increased with age, from 16.1% in those < 30 years old to 44.3% in those≥80 years old. From 2012 to 2022, the proportion of patients receiving first-line nucleos(t)ide analog antiviral treatment increased year by year, from 51.0% in 2012-2013 to 99.8% in 2022. Conclusion: The CR-HepB registration data reflect the changes in clinical characteristics and antiviral treatment patterns in patients with chronic HBV infection in China over the past ten years and can thus provide a reference to promote hepatitis B diagnosis and treatment practice, as well as scientific research.
